Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
about
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceOseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferretsResistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.Two years after pandemic influenza A/2009/H1N1: what have we learned?2009 Pandemic Influenza A (H1N1): Diagnosis, Management, and Prevention- Lessons Learned.In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, IranGenomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virusNovel (pandemic) influenza A H1N1 in healthcare facilities: implications for prevention and control.Drugs in development for influenza.Decision making with regard to antiviral intervention during an influenza pandemicD225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice.Diagnostic testing for pandemic influenza in Singapore: a novel dual-gene quantitative real-time RT-PCR for the detection of influenza A/H1N1/2009.The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation.Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitorsPandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.Screening from the world's largest TCM database against H1N1 virus.Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.The first influenza pandemic of the new millennium.Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009Comparison of characteristics of outpatients with 2009 H1N1 pandemic and seasonal influenza.Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand.In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010.The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.Influenza virus resistance to neuraminidase inhibitors: implications for treatment.The Management of the 2009 pandemic Influenza A H1N1 virus infectionPassive immune neutralization strategies for prevention and control of influenza A infections.Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus in Northern Greece.The clinical effectiveness of oseltamivir in mild cases of pandemic influenza A H1N1 2009 infection.Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan.I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275YE119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant RecipientTreatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategiesOseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients.
P2860
Q28282405-2773EC93-DCBB-4802-8BAF-216A3A0C153CQ28474889-42153E15-5FA5-41DB-B375-CB233EC7FAF4Q30151772-B6213585-65B2-4488-AC3D-70E9397100A8Q30224656-90B16B2E-F5B9-4896-BD0D-A98BF4F6EE46Q30226712-AEEB92DB-1749-403C-8DB8-1709864EFFB6Q30356466-67D5D72A-BCFC-48E0-A89C-40A08C070698Q30366471-7718F7E8-523E-430D-AFA2-1F77D7361588Q30386561-D15FFB8C-228B-4DDE-B045-4847F1D3C1D1Q30387212-A8B47E3A-EFAE-42A2-9168-B471501BE381Q30391218-1ACF1420-D54A-44A9-9DCC-9BCDC0B8452CQ30391440-76681BCC-2ABB-41F9-AD3E-34549736FD4FQ30391849-38CCBC05-69F7-4991-A5A3-EFDD9E5CE601Q30392355-00F042EB-EE41-44E7-880A-435DE5043E32Q30396361-8937CDEC-70B6-487C-9B84-FFDCCF35BAEFQ30396915-5C7A78F0-1A6B-4BB5-B03D-94B4002A509FQ30397253-5AD32D90-4129-4C4E-B2D5-E647F8D38798Q30397718-2C29869E-F04E-4B8B-A9A3-AA9ADCD53FFCQ30398715-27413741-42AD-48F5-B380-0D99A2D1CD97Q30399274-93A36370-E7A5-4D3C-BD09-982A09655700Q30399321-1B855D3A-639E-411B-A87C-D6D5E7C7EEBDQ30399346-D1686C96-66D4-43A4-B94C-57EDD272AD34Q30400621-2A16443A-E347-4B59-B9A2-81CD3A712C2CQ30401658-26D64426-91D8-42AA-8C02-9D0CDBDACFBAQ30402874-6BDC1C00-9F07-4D0F-B823-E669B9BDC33EQ30404917-92EE60E8-F963-44FF-8FBE-4228E4E67C86Q30405714-1E39FB97-18F6-493A-B3C3-CB8B89735D44Q30407184-E2A45762-09A7-433A-A010-C54E2FDA10EEQ30408174-3D32DB17-EB4D-4666-8ECC-0F246941854CQ30410229-DD44DF55-48E4-4364-AD09-7CEADC594424Q30411822-6283E0E5-72B0-4E25-984A-9791D7E49F96Q30412410-A3E9357E-E5FF-475C-B16B-26B96DCD4BE3Q30413158-CDB2E9A5-E393-484C-BA89-F0EE027BD1D2Q30414483-37968D56-ED49-4B9A-8814-F4E39F248F89Q30415310-53EF3D72-BF4C-4189-B6C3-D7D8D7D626D5Q30418830-F380E677-C1E4-48E3-A3CC-968E0DC8011AQ30420810-EB4B50E1-6479-4CAD-A44F-DCCD0F91BC6EQ36250190-3D6A1E7C-5A82-4603-836F-70589C521325Q36301052-4CC6F547-7A5B-442A-90FE-572DEB9C18B1Q38633113-AA863E93-DA30-49D6-A5C5-83F8D4F389F3Q39838350-55FC8AE8-68F2-4849-823B-9BCAFBD5F375
P2860
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
@ast
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
@en
type
label
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
@ast
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
@en
prefLabel
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
@ast
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.
@en
P2093
P2860
P356
P1476
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China
@en
P2093
Chung Lam Cheung
Jasper F W Chan
Kwok Hung Chan
Pengxi Zhao
Vincent C C Cheng
P2860
P304
P356
10.3201/EID1512.091057
P577
2009-12-01T00:00:00Z